The Effect of the RMAT Designation on Biotechnology Stock Prices, Drug Development Timelines and Outcomes: An Empirical Analysis
Joab Williamson, Alexander James Spicer & Pierre-Albert Colcomb · Journal of Pharmaceutical Research International · 2024
This research examines the impact of the U.S. FDA's Regenerative Medicine Advanced Therapy (RMAT) designation on biotechnology and small pharmaceutical companies, focusing on both stock price reactions and drug development timelines. The research employs an event-study methodolog...
Open access
Research Article
10.9734/jpri/2024/v36i97572